Stifel Nicolaus Downgrades Alexion Pharmaceuticals (ALXN) to Hold

By Jason Carr

Alexion Pharmaceuticals (NASDAQ: ALXN) received a Hold rating and a $130 price target from Stifel Nicolaus analyst Stephen Willey today. The company’s shares closed yesterday at $123.36.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.5% and a 50.7% success rate. Willey covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Akcea Therapeutics Inc, and Spark Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alexion Pharmaceuticals with a $156.75 average price target, which is a 27.1% upside from current levels. In a report issued on July 26, Jefferies also reiterated a Hold rating on the stock with a $123 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $149.34 and a one-year low of $102.10. Currently, Alexion Pharmaceuticals has an average volume of 1.37M.

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma.